Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02570932|
Recruitment Status : Completed
First Posted : October 7, 2015
Last Update Posted : April 5, 2018
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injury||Biological: Autologous Mesenchymal Bone Marrow Cell||Phase 2|
This is a clinical trial phase II, single-center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury.
Patients are treated with repeated administrations of in vitro expanded autologous adult bone marrow mesenchymal stem cells.
The expanded cells are administered in the subarachnoid space by lumbar puncture. The minimum duration of the follow-up period for each patient is 10 months after the first administration.
The study duration is 24 months, that include recruiting, treatment and follow period for all patients. For each patient at the first day will be administered the first cellular doses, then 3 doses will be administrated every 3 months. At the end of the clinical trial, a completed check of all obtained parameters will be performed.
It is considered Day 1 for each patient the first day of the first cell administration. The remaining 2 doses will be administered at intervals of 3 months from the first administration (of the treatment period after, months 4 and 7). At the end of the study will be performed a full assessment of the variables collected along the study trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intrathecal Administration (Pattern 100/3) of Expanded Autologous Adult Bone Marrow Mesenchymal Stem Cells in Established Chronic Spinal Cord Injuries|
|Study Start Date :||July 2015|
|Actual Primary Completion Date :||December 4, 2017|
|Actual Study Completion Date :||December 4, 2017|
Experimental: Autologous Mesenchymal Bone Marrow Cell
All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)
Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration.
Biological: Autologous Mesenchymal Bone Marrow Cell
Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.
Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration
- Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation. [ Time Frame: from baseline until the end of the follow up period (24 months) ]
Efficacy evaluation by measuring the change in motor and sensory functions by using the international Association of Neurorestoratology-Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS). This scale includes 9 categories with 16 items in total (plus one optional category).
The maximum possible score is 48; the lowest possible score is 0.
- Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment [ Time Frame: from baseline to 24 months ]The clinical evaluation of possible adverse effects is performed throughout the entire study duration and will be measured by descriptive analysis
- Changes in PENN score are considerate for the motor and sensory functions evaluation [ Time Frame: from baseline until the end of the follow up period (24 months) ]Efficacy evaluation by measuring the change in motor and sensory functions by using the Penn Spasm Frequency Scale that is Composed of 2-parts: the first is a self-report measure with items on 5-point scales developed to augment clinical ratings of spasticity and provides a more comprehensive assessment of spasticity
- Changes in VAS score are considerate for quantification of pain [ Time Frame: from baseline until the end of the follow up period (24 months) ]Efficacy evaluation by measuring the change in pain by using the visual analogue scale (VAS). The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, depending on his feel of pain.
- Changes in BDS score are considerate for the Assessment of the functional status [ Time Frame: from baseline until the end of the follow up period (24 months) ]Efficacy evaluation by measuring the change in the Blepharospasm Disability Scale (BDS)
- Changes in GEFFNER score are considerate for the Assessment of the functional status [ Time Frame: from baseline until the end of the follow up period (24 months) ]Efficacy evaluation by measuring the change in the GEFFNER score
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Spinal cord injury (Level A, B, C or D in ASIA scales), clinically stable for at least 6 months prior to study start.
- Previous studies of Neurophysiology, MRI and Urology to allow useful baseline, in order that they can be compared with the same scans following treatment, and to obtain objective data of potential efficacy.
- Age between 18 and 70 years.
- Men and women of childbearing age must compromise to use contraceptives from the time at which the removal of cells from the bone marrow is performed until 6 months after the Mesenchymal Stem Cells (MSC) last administration by lumbar puncture.
- Possibility of follow up and ability to perform ambulatory physical therapy throughout all treatment period.
- Written informed consent, according to the law in force.
- Hematologic, creatinine, Serum glutamic oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT) parameters, within the normal range, according to laboratory standards. However, slight modifications that are considered significant in the context of treatment to be performed, according to the criterion of the research team, are accepted.
- Age below 18 years or above 70.
- Pregnancy or lactation.
- Current neoplastic disease or in the previous 5 years (diagnosed or treated).
- Patients with systemic disease that represents an added risk to treatment.
- Alterations in the genetic study performed to discard risk cell transformation in the expansion process.
- Patients with doubts about possible cooperation in the maintenance physical therapy or in the controls carried out during the study
- Neurodegenerative disease added.
- History of substance abuse, psychiatric disease or allergy to protein products used in the process of cell expansion.
- Positive serology for HIV and syphilis.
- Active Hepatitis B or Hepatitis C, according to serology analysis.
- If in the opinion of the researcher there is some other reason why the patient is not considered candidate for the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02570932
|Hospital Puerta de Hierro|
|Majadahonda, Madrid, Spain, 28222|
|Principal Investigator:||Jesús JV Vaquero Crespo, MD.||Hospital Universitario Puerta de Hierro-Majadahonda|
|Responsible Party:||Jesús Vaquero Crespo, M.D., Principal Investigator, Puerta de Hierro University Hospital|
|Other Study ID Numbers:||
2014-005613-24 ( EudraCT Number )
|First Posted:||October 7, 2015 Key Record Dates|
|Last Update Posted:||April 5, 2018|
|Last Verified:||April 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication|
|Time Frame:||Starting at CTD submission to authorities.|
|Access Criteria:||Spanish competent authority.|
Adult Autologous Bone Marrow Mesenchymal Cells Expanded
chronic spinal cord injury (SCI)
Spinal Cord Injuries
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System